CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Ergot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist
Updated · Methodology
Mechanism
Ergotamine and dihydroergotamine are both ergot alkaloids, and both constrict blood vessels. Ergotamine constricts dilated cranial arteries and on its own can cause myocardial ischaemia, or rarely infarction, even in people with no known coronary heart disease (ergotamine with caffeine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dihydroergotamine acts on 5-HT1D serotonin receptors, and its main metabolite is as potent a venoconstrictor as the parent drug. Like other ergot alkaloids, dihydroergotamine can cause coronary and other arterial spasm (dihydroergotamine labels, US Food and Drug Administration, FDA). The Spanish ergotamine SmPC states that other ergot preparations and other vasoconstrictors may raise the risk of vasoconstriction (AEMPS). The US dihydroergotamine labels state that combining dihydroergotamine with vasoconstrictors may raise blood pressure because their effects add up or reinforce each other (FDA). The documents give no data on whether one drug changes the blood level of the other.
Symptoms
Vasospasm from ergotamine starts with numbness and tingling in the fingers and toes, headache and chest pain (ergotamine with caffeine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dihydroergotamine can cause muscle pain, numbness, coldness, pallor and bluish discolouration of the fingers and toes, as well as myocardial, limb and colonic ischaemia. Myocardial infarction, ventricular tachycardia and ventricular fibrillation have been reported, and on rare occasions blood pressure rises sharply (dihydroergotamine labels, US Food and Drug Administration, FDA). In ergotism, intense arterial constriction makes the limbs numb, painful and bluish, and their pulses weaken or disappear. Renal and cerebral vasospasm can also occur, and without treatment gangrene can develop (ergotamine with caffeine SmPC, AEMPS; dihydroergotamine labels, FDA). Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA).
Management
The combination is contraindicated (ergotamine with caffeine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; dihydroergotamine labels, US Food and Drug Administration, FDA). The Spanish ergotamine SmPC contraindicates ergotamine with vasoconstrictors, including ergot alkaloids, and names dihydroergotamine among the products to avoid if another migraine drug is needed for the same attack (AEMPS). The US labels contraindicate dihydroergotamine if the patient has taken ergotamine-containing or other ergot-type medicines in the previous 24 hours. The dihydroergotamine nasal spray label states that these drugs should not be used within 24 hours of each other (FDA). Dihydroergotamine is not in the Spanish medicines register. Warn the patient about the ergotamine dose limits, no more than 6 mg a day and 10 mg a week, and about the signs of vasospasm: numbness and tingling in the fingers and toes, headache and chest pain. Tell them to stop taking ergotamine at once if these appear (ergotamine with caffeine SmPC, AEMPS). If signs of vasospasm appear, stop ergotamine and start a peripheral vasodilator (ergotamine with caffeine SmPC, AEMPS). Stop dihydroergotamine at once if signs of vasoconstriction appear (dihydroergotamine labels, FDA). For severe vasospasm, give the vasodilator intravenously, warm the affected area and protect the tissue from damage. For coronary constriction, start treatment, for example with nitroglycerin (ergotamine with caffeine SmPC, AEMPS, overdose section). Both drugs are contraindicated in uncontrolled hypertension (ergotamine with caffeine SmPC, AEMPS; dihydroergotamine labels, FDA). Taking acute migraine drugs, including ergot drugs, on 10 or more days a month can make headaches more frequent (dihydroergotamine labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- AEMPS: Ficha técnica: Ergotamina/cafeína (nº registro 17558), sección 4.3 (2025)– AEMPS, CIMA, nº registro 17558 (Cafergot 1 mg/100 mg comprimidos, Amdipharm), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- FDA: Dihydroergotamine mesylate nasal spray, Cipla (dihydroergotamine) prescribing information (2025)– FDA, DailyMed setid 1ecb2311-eee3-4230-a019-a3496308cff1 (Cipla USA), versión 10 (SPL 29.12.2025, texto revisado 05/2022), Contraindications